HRP20070241T3 - Azabiciklički heterocikli kao modulatori kanabinoid receptora - Google Patents
Azabiciklički heterocikli kao modulatori kanabinoid receptoraInfo
- Publication number
- HRP20070241T3 HRP20070241T3 HR20070241T HRP20070241T HRP20070241T3 HR P20070241 T3 HRP20070241 T3 HR P20070241T3 HR 20070241 T HR20070241 T HR 20070241T HR P20070241 T HRP20070241 T HR P20070241T HR P20070241 T3 HRP20070241 T3 HR P20070241T3
- Authority
- HR
- Croatia
- Prior art keywords
- group
- cycloalkylalkyl
- arylalkyl
- cycloalkyl
- alkyl
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 title abstract 7
- 239000003520 cannabinoid receptor affecting agent Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000000304 alkynyl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
Spoj formule Iuključujući farmaceutski prihvatljive soli i stereoizomere, naznačen time, da je: n jednostruka veza ili dvostruka veza, R1 je izabran iz skupine koja se sastoji od halogen, cijano, alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil,heterociklil, heterociklilalkil, aril, arilalkil,heteroaril, heteroarilalkil, ariloksi, heteroariloksi, -NR8R9, -CO2R8, CONR8R9, -OR8, -NR8COR9, -NR8CONR8R9, -NR8CO2R9, -OCONR8R9, NR8S(O)mR9, -NR8S(O)mR8R9, -NR8S(O)mOR9 i -OS(O)mNR8R9;R2 je izabraniz skupine koja se sastoji od halogen, cijano, alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heterociklil, heterociklilalkil, aril, arilalkil, heteroaril, heteroarilalkil, ariloksi, heteroariloksi, -NR8R9, -CO2R8, CONR8R9, -OR8, -NR8COR8, -NR8CONR8R9, -NR8CO2R9, -OCONR8R9, NR8S(O)mR9, -NR8S(O)mR8R9, -NR8S(O)mOR9 i -OS(O)mNR8R9;R3 je izabran iz skupine koja se sastoji od alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heterociklilalkil, arilalkil i heteroarilalkila; R6 je izabran iz skupine koja se sastoji od H, alkil, cikloalkil,heterociklil, cikloalkilalkil, heterocikloalkil, aril, heteroaril, arilalkil i heteroarilalkila, gdje R6 skupina ima molekularnu masu manju od 200 atomskih jedinica mase; R7 je odsutan kada je n dvostruka veza; R7 je izabran iz skupine koja se sastoji od H, alkil, cikloalkil, heterociklil, cikloalkilalkil, heterocikloalkil, aril, heteroaril, arilalkil, heteroarilalkil, -COR8, -CO2R8, -CONR8R9 i -S(O)mR8 kada je n jednostruka veza; R8 i R9 su neovisno izabrani iz skupine koja se sastoji od H, alkil, aril, arilalkil, cikloalkil, cikloalkilalkil,heterociklil, heterocikloalkil, heteroaril i heteroarilalkila, R8 i R9 uzeti zajedno mogu opcijski tvoriti heterociklički prsten od 4, 5, 6 ili 7 članova ili heteroarilni prsten od 5 ili 6 članova; im je cijeli broj koji je 1 ili 2. Patent sadrži još 73 patentna zahtjeva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53145103P | 2003-12-19 | 2003-12-19 | |
PCT/US2004/042820 WO2005063761A1 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
US11/016,135 US7378418B2 (en) | 2003-12-19 | 2004-12-17 | Azabicyclic heterocycles as cannabinoid receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20070241T3 true HRP20070241T3 (hr) | 2007-07-31 |
Family
ID=34703659
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20070241T HRP20070241T3 (hr) | 2003-12-19 | 2007-05-25 | Azabiciklički heterocikli kao modulatori kanabinoid receptora |
Country Status (20)
Country | Link |
---|---|
US (1) | US7378418B2 (hr) |
EP (1) | EP1697370B1 (hr) |
JP (1) | JP2007514768A (hr) |
AT (1) | ATE360630T1 (hr) |
AU (1) | AU2004309365A1 (hr) |
BR (1) | BRPI0417771A (hr) |
CA (1) | CA2550435A1 (hr) |
CY (1) | CY1106674T1 (hr) |
DE (1) | DE602004006165T2 (hr) |
DK (1) | DK1697370T3 (hr) |
ES (1) | ES2282927T3 (hr) |
HK (1) | HK1095139A1 (hr) |
HR (1) | HRP20070241T3 (hr) |
IL (1) | IL176107A0 (hr) |
IS (1) | IS8502A (hr) |
NO (1) | NO20062704L (hr) |
PL (1) | PL1697370T3 (hr) |
PT (1) | PT1697370E (hr) |
RU (1) | RU2006126122A (hr) |
WO (1) | WO2005063761A1 (hr) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100210590A1 (en) * | 1995-09-27 | 2010-08-19 | Northwestern University | Compositions and treatments for seizure-related disorders |
US20030176437A1 (en) | 2001-08-31 | 2003-09-18 | D.M. Watterson | Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
CN1875021A (zh) * | 2003-11-04 | 2006-12-06 | 默克公司 | 取代的萘啶酮衍生物 |
ES2441718T3 (es) | 2004-11-02 | 2014-02-06 | Northwestern University | Compuestos de piridazina, composiciones y métodos |
WO2006050359A2 (en) * | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
US8361999B2 (en) * | 2005-04-04 | 2013-01-29 | Pontificia Universidad Catolica De Chile | Methods of treating cholesterol gallstone disease with ezetimibe |
US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
WO2007080720A1 (ja) * | 2005-12-07 | 2007-07-19 | Sumitomo Chemical Company, Limited | ピリダジン化合物およびその用途 |
AU2006326815A1 (en) * | 2005-12-20 | 2007-06-28 | Merck Frosst Canada Ltd. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase |
US20090264470A1 (en) * | 2006-02-21 | 2009-10-22 | Bennett Teresa A | CB1 Antagonists and Inverse Agonists |
CN101754762A (zh) | 2006-04-28 | 2010-06-23 | 西北大学 | 用于治疗神经炎症性疾病的包含哒嗪化合物的制剂 |
EP2015750A2 (en) * | 2006-04-28 | 2009-01-21 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
US7705154B2 (en) * | 2006-11-30 | 2010-04-27 | Dow Agrosciences Llc | Process for the preparation of 2-substituted-5-(1-alkylthio)alkylpyridines |
EP1974608A1 (de) * | 2007-03-30 | 2008-10-01 | Bayer CropScience AG | Arylpyridazine als Fungizide |
US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
JP5548120B2 (ja) * | 2007-04-11 | 2014-07-16 | オメロス コーポレーション | 嗜癖の予防および治療のための組成物および方法 |
ES2439255T3 (es) * | 2007-06-21 | 2014-01-22 | Cara Therapeutics, Inc. | Imidazoheterociclos sustituidos |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CA2698808A1 (en) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
EP2042491A1 (de) * | 2007-09-14 | 2009-04-01 | Bayer CropScience AG | Pyridazine als Fungizide |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
CN101590239B (zh) * | 2008-05-30 | 2013-03-27 | 北京奥萨医药研究中心有限公司 | 含有利尿剂、他汀和叶酸的药物组合物及其用途 |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010018874A1 (en) * | 2008-08-12 | 2010-02-18 | Takeda Pharmaceutical Company Limited | Amide compound |
US20100113603A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
WO2010045522A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
WO2010045529A2 (en) * | 2008-10-16 | 2010-04-22 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
US20100113583A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100113604A1 (en) * | 2008-10-16 | 2010-05-06 | Aronne Louis J | Combination therapies for the treatment of obesity |
US20100331419A1 (en) * | 2009-06-25 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20100331420A1 (en) * | 2009-06-26 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
US20100331999A1 (en) * | 2009-06-29 | 2010-12-30 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
WO2011009115A2 (en) * | 2009-07-17 | 2011-01-20 | Metabolous Pharmaceuticals, Inc. | Combination therapies for the treatment of obesity |
EP2483407A2 (en) | 2009-09-30 | 2012-08-08 | President and Fellows of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products |
US20110082407A1 (en) * | 2009-10-01 | 2011-04-07 | Aronne Louis J | Combination Therapies for the Treatment of Obesity |
TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
WO2011078360A1 (ja) * | 2009-12-24 | 2011-06-30 | 武田薬品工業株式会社 | アミド化合物 |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
KR101898610B1 (ko) | 2010-08-31 | 2018-09-14 | 서울대학교산학협력단 | PPARδ 활성물질의 태자 재프로그래밍 용도 |
ES2552879T3 (es) * | 2010-11-08 | 2015-12-02 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
WO2012087372A1 (en) | 2010-12-22 | 2012-06-28 | E. I. Du Pont De Nemours And Company | Fungicidal 2-(bicyclic aryloxy)carboxamides |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
SI2978859T1 (sl) | 2013-03-27 | 2018-10-30 | F. Hoffmann-La Roche Ag | Genetski označevalci za napovedovanje odzivnosti na terapijo |
JP6854752B2 (ja) | 2014-07-30 | 2021-04-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Hdl上昇剤又はhdl模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
PL3464318T3 (pl) | 2016-06-02 | 2021-11-08 | Abbvie Inc. | Agonista receptora glukokortykoidowego i jego immunokoniugaty |
US11584744B2 (en) * | 2017-06-23 | 2023-02-21 | University Of Washington | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them |
US10772970B2 (en) | 2017-12-01 | 2020-09-15 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
KR102538572B1 (ko) * | 2018-06-15 | 2023-06-01 | 화이자 인코포레이티드 | Glp-1 수용체 효능제 및 그의 용도 |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994898A (en) * | 1975-10-16 | 1976-11-30 | E. R. Squibb & Sons, Inc. | 1,2,4-Triazolo (4,3-b) pyridazin-3-ones |
US4515791A (en) * | 1980-06-03 | 1985-05-07 | American Cyanamid Company | Substituted phenyl-1,2,4-triazolo[2,3-b]pyridazin-3(2H)ones as anti-asthma agents |
JPS61106576A (ja) * | 1984-10-31 | 1986-05-24 | Nippon Soda Co Ltd | トリアゾロピリダジン−3−オン誘導体及び製造方法 |
CA2346659A1 (en) * | 1998-10-06 | 2000-04-13 | Michiyo Gyoten | Condensed pyridazine compounds, their production and use |
JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
EP1594848A1 (en) | 2003-02-19 | 2005-11-16 | Neurogen Corporation | Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |
-
2004
- 2004-12-17 US US11/016,135 patent/US7378418B2/en active Active
- 2004-12-17 JP JP2006545558A patent/JP2007514768A/ja not_active Withdrawn
- 2004-12-17 PT PT04814952T patent/PT1697370E/pt unknown
- 2004-12-17 DK DK04814952T patent/DK1697370T3/da active
- 2004-12-17 BR BRPI0417771-1A patent/BRPI0417771A/pt not_active IP Right Cessation
- 2004-12-17 CA CA002550435A patent/CA2550435A1/en not_active Abandoned
- 2004-12-17 RU RU2006126122/04A patent/RU2006126122A/ru not_active Application Discontinuation
- 2004-12-17 EP EP04814952A patent/EP1697370B1/en active Active
- 2004-12-17 PL PL04814952T patent/PL1697370T3/pl unknown
- 2004-12-17 ES ES04814952T patent/ES2282927T3/es active Active
- 2004-12-17 AU AU2004309365A patent/AU2004309365A1/en not_active Abandoned
- 2004-12-17 AT AT04814952T patent/ATE360630T1/de not_active IP Right Cessation
- 2004-12-17 WO PCT/US2004/042820 patent/WO2005063761A1/en active Application Filing
- 2004-12-17 DE DE602004006165T patent/DE602004006165T2/de not_active Expired - Fee Related
-
2006
- 2006-06-04 IL IL176107A patent/IL176107A0/en unknown
- 2006-06-08 IS IS8502A patent/IS8502A/xx unknown
- 2006-06-12 NO NO20062704A patent/NO20062704L/no not_active Application Discontinuation
-
2007
- 2007-02-16 HK HK07101919A patent/HK1095139A1/xx not_active IP Right Cessation
- 2007-05-25 HR HR20070241T patent/HRP20070241T3/hr unknown
- 2007-06-21 CY CY20071100832T patent/CY1106674T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2004309365A1 (en) | 2005-07-14 |
EP1697370A1 (en) | 2006-09-06 |
ES2282927T3 (es) | 2007-10-16 |
US7378418B2 (en) | 2008-05-27 |
DK1697370T3 (da) | 2007-09-17 |
IS8502A (is) | 2006-06-08 |
HK1095139A1 (en) | 2007-04-27 |
PL1697370T3 (pl) | 2007-09-28 |
DE602004006165T2 (de) | 2008-01-17 |
WO2005063761A1 (en) | 2005-07-14 |
CA2550435A1 (en) | 2005-07-14 |
NO20062704L (no) | 2006-09-05 |
JP2007514768A (ja) | 2007-06-07 |
PT1697370E (pt) | 2007-05-31 |
IL176107A0 (en) | 2006-10-05 |
US20050143381A1 (en) | 2005-06-30 |
BRPI0417771A (pt) | 2007-04-17 |
RU2006126122A (ru) | 2008-01-27 |
EP1697370B1 (en) | 2007-04-25 |
CY1106674T1 (el) | 2012-05-23 |
ATE360630T1 (de) | 2007-05-15 |
DE602004006165D1 (de) | 2007-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20070241T3 (hr) | Azabiciklički heterocikli kao modulatori kanabinoid receptora | |
HRP20070267T3 (hr) | Azabiciklički heterocikli kao modulatori kanabinoid receptora | |
AR047063A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide | |
RS52953B (en) | PYRIDOPINIDINONSKI INHIBITORI PI3 KALFA | |
NO20051411L (no) | Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav | |
HRP20080541T3 (hr) | Piperazinski derivati i njihova upotreba u liječenju neuroloških i psihijatrijskih bolesti | |
HRP20010573B1 (hr) | Triciklički inhibitori poli(adp-riboza) polimeraza | |
GB0212048D0 (en) | Therapeutic agents | |
RS52865B (en) | Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors | |
RS51471B (en) | BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | |
NO20025955D0 (no) | 1,2-dihydropyridinforbindelser, fremgangsmåte for fremstilling av de sammeog anvendelse derav | |
WO2003037862A1 (fr) | Derives amide, et medicaments correspondants | |
EP0040639A4 (en) | ISOXAZOLE DERIVATIVES. | |
AU2352495A (en) | Condensed heterocyclic compounds, their production and use as gnrh antagonists | |
AR049699A1 (es) | Derivados de pirimidina | |
AU1253002A (en) | Imidazo-triazine derivatives as ligands for gaba receptors | |
RS52091B (sr) | Izoksazolinski derivati i herbicidi koji sadrže iste kao aktivne sastojke | |
HRP20080227T3 (hr) | Pirolidinski derivati kao ligandi histaminskih receptora | |
EP1354880A4 (en) | HALOGEN COMPOUNDS HAVING AGONISM TOWARDS THROMBOPOIETIN RECEPTOR | |
WO2003034997A3 (en) | Modulators of phosphoinositide 3-kinase | |
ATE271868T1 (de) | Neue cathechole als antimikrobielle mittel | |
ATE503746T1 (de) | Neue imidazolidinderivate | |
WO2006030211A3 (en) | Acyclic sulphonamides | |
WO2008155670A3 (en) | Arylamide pyrimidone compounds | |
GB0117277D0 (en) | Therapeutic agents |